Stock Price & Analysis

Buy HSIC stock as it shows positive momentum with a recent price increase of +1.73% and favorable technical indicators. The stock is supported by potential dental demand growth due to legislative changes and an upcoming meeting with Oppenheimer.

HSIC stock is predicted to reach $78 by Q4 2025, driven by potential dental demand growth from legislative changes like Utah's water fluoridation ban. The stock currently trades at $71.8, with a Fibonacci resistance level at $72.94, suggesting moderate upside potential.

The S1 support level for HSIC Stock is $69.65 ,The R1 resistant level for HSIC Stock is $76.35.

As of the end of day on 2025-03-19, the price of HSIC Stock was $72.49.

The target price for HSIC Stock according to analyst rating is 80.00, with the highest price target at 90.00 and the lowest at 55.00. Analysts have a Hold rating on HSIC Stock overall.

The market cap of HSIC is $8.9B.

Analysis and Insights

HSIC appears overvalued based on several factors:

1. High Valuation Metrics: HSIC's P/E ratio of 23.07 and EV/EBITDA of 12.08 are above industry averages, indicating a premium valuation.

2. Mixed Analyst Sentiment: While some analysts maintain a 'Buy' rating, others have 'Hold' or 'Sell' ratings, reflecting uncertainty.

3. Negative Organic Growth: HSIC has experienced nine quarters of negative organic growth, raising concerns about its growth prospects.

4. Recent News Impact: Although Utah's water fluoridation ban could boost dental demand, it may not significantly impact HSIC's current valuation.

Conclusion

HSIC's high valuation and mixed analyst sentiment suggest it may be overvalued. Investors should exercise caution and consider waiting for a price correction or improved fundamentals before investing.

Henry Schein, Inc. is a solutions company for health care professionals powered by a network of people and technology. The Company operates through two segments: health care distribution, and technology and value-added services. The health care distribution segment distributes consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, personal protective equipment products (PPE) and vitamins. The technology and value-added services segment provides software, technology and other value-added services to health care practitioners. It offers dental practice management solutions for dental and medical practitioners. In addition, it offers dentists and physicians a suite of electronic health records and patient communication services.

HSIC stock is predicted to reach $85 by 2030, driven by analyst optimism and potential industry growth. The current price of $71.8, combined with a Fibonacci pivot of $72.94, suggests upside potential. Analysts' price targets and positive legislative changes support this long-term outlook.

HSIC has a total of 25000 employees.